We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App





Smartphone-Powered, Saliva-Based COVID-19 Diagnostic Test Delivers Lab-Quality Results to App in 20 Minutes

By LabMedica International staff writers
Posted on 18 Jun 2020
Print article
Illustration
Illustration
A portable, saliva-based COVID-19 diagnostic test will be able to detect COVID-19 infection in less than 20 minutes, with an easy-to-use device that can be employed in a variety of settings.

The COVID-19 diagnostic test called Atlas is being developed by Nicoya (Ontario, Canada) with funding from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP). Nicoya will receive up to USD 299,190 in funding to develop the portable COVID-19 diagnostic test that will expand testing capabilities in centralized settings (such as hospital and testing laboratories) as well as point-of-care settings (such as local clinics and long-term care homes).

The development of an Atlas prototype is currently underway at Nicoya. The company is leveraging its deep expertise in areas such as nanotechnology, microfluidics and biochemistry to develop Atlas as a viable solution for containing COVID-19 and preventing the spread of future viral diseases. Atlas will be a single-use, disposable device that will detect active infection by testing for SARS-CoV-2 viral proteins. To make the test as accessible as possible, Nicoya is powering it with smartphone technology so that it can deliver lab-quality results to an app in less than 20 minutes. The test will be performed with a saliva sample, rather than the more common nasopharyngeal swab samples. With Atlas, Nicoya hopes to make testing more available everywhere, from remote communities to front-line screening procedures.

“Our government is mobilizing resources to combat COVID-19 and I’m proud that Nicoya was one of four Phase I funding recipients of the Point-of-Care Diagnostic Test Kit Challenge,” said Raj Saini, Member of Parliament for Kitchener Centre. “Nicoya is an exemplary company already working hard on pioneering innovative research and finding solutions together, and this approach is a pillar to ensuring we have both short and long-term solutions to fight the COVID-19 pandemic.”

Related Links:
Nicoya

Gold Member
Universal Transport Solution
Puritan®UniTranz-RT
Automated Blood Typing System
IH-500 NEXT
New
Herpes Virus Test
Human Herpes Virus (HHV-6) Real Time PCR Kit
New
Vibrio Cholerae O1/O139 Rapid Test
StrongStep Vibrio Cholerae O1/O139 Antigen Combo Rapid Test

Print article

Channels

Clinical Chemistry

view channel
Image: The new saliva-based test for heart failure measures two biomarkers in about 15 minutes (Photo courtesy of Trey Pittman)

POC Saliva Testing Device Predicts Heart Failure in 15 Minutes

Heart failure is a serious condition where the heart muscle is unable to pump sufficient oxygen-rich blood throughout the body. It ranks as a major cause of death globally and is particularly fatal for... Read more

Hematology

view channel
Image: The smartphone technology measures blood hemoglobin levels from a digital photo of the inner eyelid (Photo courtesy of Purdue University)

First-Of-Its-Kind Smartphone Technology Noninvasively Measures Blood Hemoglobin Levels at POC

Blood hemoglobin tests are among the most frequently conducted blood tests, as hemoglobin levels can provide vital insights into various health conditions. However, traditional tests are often underutilized... Read more

Immunology

view channel
Image: Under a microscope, DNA repair is visible as bright green spots (“foci”) in the blue-stained cell DNA. Orange highlights actively growing cancer cells (Photo courtesy of WEHI)

Simple Blood Test Could Detect Drug Resistance in Ovarian Cancer Patients

Every year, hundreds of thousands of women across the world are diagnosed with ovarian and breast cancer. PARP inhibitors (PARPi) therapy has been a major advancement in treating these cancers, particularly... Read more

Microbiology

view channel
Image: HNL Dimer can be a novel and potentially useful clinical tool in antibiotic stewardship in sepsis (Photo courtesy of Shutterstock)

Unique Blood Biomarker Shown to Effectively Monitor Sepsis Treatment

Sepsis remains a growing problem across the world, linked to high rates of mortality and morbidity. Timely and accurate diagnosis, along with effective supportive therapy, is essential in reducing sepsis-related... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.